Premium
Treatment for Stage III–IV Neuroblastoma Patients: Initial Response to Chemotherapy Evaluated by Biochemical Parameters
Author(s) -
IMASHUKU S.,
TODO S.,
NAKAJIMA F.,
FUJITA K.,
HIBI S.,
MIYAKE M.
Publication year - 1991
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1991.tb11754.x
Subject(s) - vanillylmandelic acid , medicine , vincristine , neuroblastoma , chemotherapy , enolase , cyclophosphamide , stage (stratigraphy) , cisplatin , homovanillic acid , doxorubicin , etoposide , urinary system , induction chemotherapy , urology , gastroenterology , oncology , paleontology , receptor , immunohistochemistry , biology , serotonin , genetics , cell culture
. Fourteen patients with stage III–IV neuroblastoma were treated with alternating combination chemotherapy consisting of (a) VP16/cisplatin and (b) doxorubicin/vincristine/cyclophosphamide. The initial response to induction chemotherapy, especially to VP16/cisplatin was evaluated by determining t 1/2 for urinary vanillylmandelic acid (VMA), homovanillic acid and serum neuron specific enolase (NSE). The period prior to normalization of these parameters was also determined. The patients could be classified as 7 rapid responders, with less than 3 weeks oft 1/2 VMA, or t 1/2 NSE, and 7 slow responders longer than 4 weeks of t 1/2 VMA. An analysis of the data indicates that an initial rapid response correlated with subsequent high complete response rate, but did not necessarily predict better prognosis in these patients.